September 28, 2019 04:01 AM EDTUpdated 04:16 AM
Deals
Bioregnum
FDA+
Opinion

An­oth­er big bio­phar­ma merg­er runs in­to an­oth­er snag at the FTC. What now?

It’s Ab­b­Vie’s turn to get hit with a dread­ed sec­ond re­quest for in­for­ma­tion from the FTC re­gard­ing its $63 bil­lion megamerg­er with Al­ler­gan. …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

A service from the Financial Times